Navigation Links
NIH researchers highlight progress, path forward for developing TB vaccines
Date:3/19/2012

In the past decade, scientists have made significant progress building the critical knowledge and infrastructure needed to identify and develop novel tuberculosis (TB) vaccine candidates and move the most promising ones into human clinical trials. The results of those trials, coupled with advances from other TB studies, have paved the way for the next 10 years of research on TB vaccines, a critical component of TB control efforts, note scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Their editorial, co-authored by NIAID Director Anthony S. Fauci, M.D., and Christine Sizemore, Ph.D., appears in the journal Tuberculosis to coincide with the publication of Tuberculosis Vaccines: A Strategic Blueprint for the Next Decade.

The new Blueprint on TB vaccines updates the original one, which was published in 2000 as the result of an NIH-sponsored workshop.

Since that time, TB researchers have assembled a significant pipeline of vaccine candidates and assessed them in clinical trials. However, to transform the field and help make licensure of new vaccines a reality, the editorial co-authors stress, scientists must investigate remaining fundamental questions, including the following:

  • Why does infection with the TB bacterium cause active disease in some people but not others?
  • Why does the current licensed TB vaccine, Bacille Calmette-Gurin, protect children more effectively than adults?
  • What immune responses must effective vaccines elicit to successfully protect against TB?

NIAID, part of the team that helped to develop both iterations of the Blueprint, supports scientists working worldwide to contribute important data to these and other areas of inquiry. The authors also note that along with basic and clinical tri
'/>"/>

Contact: Nalini Padmanabhan
padmanabhannm@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Penn researchers find mentoring provides health benefits for African American veterans with diabetes
2. Mayo Clinic researchers building melanoma vaccine to combat skin cancer
3. Evidence builds that meditation strengthens the brain, UCLA researchers say
4. Wilmot researchers create new way to study liver cancer
5. Researchers develop first theranostic treatment for acute lymphoblastic leukemia (ALL)
6. Researchers find possible genetic keys to surviving epithelial ovarian cancer
7. Researchers discover possible approach to the treatment of aggressive breast cancer
8. Researchers ID gene behind primary cervical dystonia, a neck-twisting disorder
9. Researchers find sarcoma tumor immune response with combination therapy
10. Mayo researchers provide atomic view of a histone chaperone
11. Researchers find potential solution to melanomas resistance to vemurafenib
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... 23, 2014 BambooFlooringChina.com is a ... has proudly released its new collection of bamboo mats ... up to 29% off. , According to the ... tree-like grass, making it a highly renewable resource. Their bamboo ... a mixing color which comes from natural bamboo with caramel ...
(Date:11/22/2014)... Setria® Glutathione is now available ... for use “as a therapeutically active ingredient in ... Therapeutic Goods (Listing) Notice 2014 (No. 5) - ... Glutathione will be exclusivity distributed in Australia by ... imports fine chemicals to Australian manufacturers. TGA approval ...
(Date:11/22/2014)... Discount-Dress.com is an important company in the dress industry. ... company’s online market share by a series of promotions. Recently, ... announced a bridesmaid dress promotion for the new year 2015. ... the dresses from this company are not only of high ... very good at manufacturing wedding dresses. Customers prefer to choose ...
(Date:11/22/2014)... November 22, 2014 Nocturia is ... the complaint that the individual has to wake ... The report “Nocturia – Pipeline Review, H2 2014” ... Nocturia, complete with comparative analysis at various stages, ... (MoA), route of administration (RoA) and molecule type, ...
(Date:11/22/2014)... 22, 2014 A petition seeking a ... ) in minimally-invasive hysterectomies and fibroid removal surgeries ... end of October, Bernstein Liebhard LLP reports. According ... of November 21st, 2014. That represents an increase of ... signed on to the campaign.* , The campaign to ...
Breaking Medicine News(10 mins):Health News:Trendy Bamboo Mats Online Now By BambooFlooringChina.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:Bridesmaid Dresses Introduced by Famous Company Discount-Dress.com For The New Year 2015 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 4
... The following is a,statement by Robert Greenstein, ... Priorities, on the new congressional SCHIP agreement:, ... million,low-income uninsured children, a major accomplishment. Contrary to ... would gain coverage are poor,and near-poor children who ...
... aren,t cautioning patients on medication-associated dangers, study finds , ... childbearing age commonly take prescription drugs that can cause ... counseling from their doctors or other health care providers, ... of Pittsburgh School of Medicine are calling for increased ...
... better reading, less absenteeism with long-term treatment , , ... attention-deficit/hyperactivity disorder (ADHD) can perform better at school ... study suggests. , "This is the first study ... long-term school performance," said lead researcher Dr. William ...
... Research conducted at the University of California, San Diego ... the structure and function of one of the key ... an enzyme which plays an essential role in memory ... Utilizing a process called x-ray crystallography, the scientists solved ...
... diagnosis affects more than just the patient. A new study ... finds spouses report similar physical and emotional quality of life ... really impacted emotional distress - among both patients and their ... a recurrence or living with advanced disease. , Researchers ...
... Va. -- Based on the results of a recent ... molecular imaging/nuclear medicine research should be restored to the ... society for molecular imaging and nuclear medicine professionals. , ... Institutes of Health, the 13-month, $700,000 report was prompted ...
Cached Medicine News:Health News:Statement by Robert Greenstein, Executive Director of the Center on Budget and Policy Priorities, on the New Congressional SCHIP Agreement 2Health News:Many U.S. Women Unaware of Birth Defect Risks 2Health News:ADHD Drugs Help Boost Children's Grades 2Health News:ADHD Drugs Help Boost Children's Grades 3Health News:UCSD study reveals the regulatory mechanism of key enzyme 2Health News:Cancer patients, spouses report similar emotional distress, U-M study finds 2Health News:SNM applauds NAS study showing need to restore federal nuclear medicine research funding 2Health News:SNM applauds NAS study showing need to restore federal nuclear medicine research funding 3
(Date:11/21/2014)... 21, 2014  World Hemp Oil, an importer of ... they are now offering legal, organic oil with high ... strains grown in medical marijuana states. People suffering from ... as Parkinson,s, MS, and spinal cord injury, no longer ... because imported CBD Oil Is legal in all states. ...
(Date:11/21/2014)... 2014  Abaxis, Inc. (NasdaqGS: ABAX ), ... for the medical, research, and veterinary markets worldwide and ... markets in the United States , ... to acquire 100% of QCR & Trio Diagnostics Limited, ... organization. The transaction closed on November 17, 2014. ...
(Date:11/21/2014)... , 21. November 2014 /PRNewswire/ ... hat heute bekannt gegeben, dass die ... EMA) die Kennzeichnung als Orphan-Medizinprodukt an ... des Unternehmens zur Behandlung von Fibrodysplasia ... seltene, stark beeinträchtigende genetische Krankheit, die ...
Breaking Medicine Technology:New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3Abaxis Acquires UK-based Distribution Organization 2Abaxis Acquires UK-based Distribution Organization 3Abaxis Acquires UK-based Distribution Organization 4Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3
... 2010 Abaxis, Inc. (Nasdaq: ABAX ), ... today announced the release of a new Piccolo® reagent ... disc will be used by healthcare professionals in conjunction ... of this new panel configuration, U.S. healthcare professionals can ...
... 12, 2010 EntreMed, Inc. (Nasdaq: ... for the treatment of cancer, today reported results ... 30, 2010. (Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO) ... net loss for the third quarter of 2010 ...
Cached Medicine Technology:Abaxis Increases Reagent Disc Offering for Physician Office Market With Release of BioChemistry Panel Plus 2Abaxis Increases Reagent Disc Offering for Physician Office Market With Release of BioChemistry Panel Plus 3EntreMed Reports Third Quarter 2010 Financial Results 2EntreMed Reports Third Quarter 2010 Financial Results 3EntreMed Reports Third Quarter 2010 Financial Results 4
Female Mini-VEST Seamless, Front Closure...
Male Support Brief...
For Lipoplasty or surgery of abdomen, flanks and midriff...
Select Support Brief...
Medicine Products: